Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx(R)-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma GlobeNewswire December 09, 2025 FRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests […]

ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science Xelafaslatide was safe and well tolerated at all evaluated doses, with the potential to reduce GA lesion growth and improve vision GlobeNewswire December 09, 2025 ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) —

Gencor Releases Fourth Quarter and Fiscal Year 2025 Results GlobeNewswire December 09, 2025 ORLANDO, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the fourth quarter ended September 30, 2025 of $18.8 million, down 10.0% from $20.9 million net revenue for the

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science GlobeNewswire December 09, 2025 NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer GlobeNewswire December 09, 2025 Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (“TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line

Plug to Participate in Wells Fargo Energy & Power Conference GlobeNewswire December 09, 2025 SLINGERLANDS, N.Y., Dec. 09, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, announces its participation in the Wells Fargo Energy & Power Conference hosted in New York, New York.

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trial GlobeNewswire December 09, 2025 RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) — Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene

ALAMEDA, Calif. and UZWIL, Switzerland, Dec. 09, 2025 (GLOBE NEWSWIRE) — Pow.Bio, the pioneer in AI-enabled continuous fermentation technology, and Buhler Group, the global solution provider for food, feed, and advanced materials, are teaming up to bring an integrated continuous precision fermentation platform to market. The collaboration advances industrial biomanufacturing by accelerating process development, reducing

According to MarketsandMarkets™, the global Circuit Breaker Marketsize is projected to grow from USD 22.70 million in 2025 to USD 30.32 billion by 2030 at a compound annual growth rate (CAGR) of 6.0% during the forecast period. https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg Browse350 market data Tables and150 Figures spread through300 Pages and in-depth TOC on “Circuit Breaker Market –

Abu Dhabi , Dec. 09, 2025 (GLOBE NEWSWIRE) — ZIGChain, the Layer 1 blockchain engineered for wealth generation, and Zoniqx, which has been pioneering institutional tokenization infrastructure since 2017, today announced a partnership at RWA Connect Abu Dhabi that integrates Zoniqx's institutional tokenization platform directly into ZIGChain's blockchain network, enabling banks and asset managers to